NCT03773367View on ClinicalTrials.gov

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Fluorouracil

Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.

DRUG

Oxaliplatin

Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.

DRUG

Irinotecan

Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.

Trial Locations (4)

0450

Oslo University Hospital, Ullevål Hospital, Oslo

221 85

Lund University Hospital, Lund

141 86

Karolinska University Hospital, Stockholm

352 34

Centrallasarettet i Växjö, Vaxjo

All Listed Sponsors
lead

Lund University Hospital

OTHER

NCT03773367 - Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | Biotech Hunter | Biotech Hunter